The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
about
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinaseUbp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signalingChildhood leukemia: electric and magnetic fields as possible risk factorsImpaired DNA replication within progenitor cell pools promotes leukemogenesis.The Philadelphia chromosome in leukemogenesisA hostel for the hostile: the bone marrow niche in hematologic neoplasmsCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaAnimal models of leukemia: any closer to the real thing?Activation of tyrosine kinases by mutation of the gatekeeper threonineConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft ModelsCooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemiaTyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cellsMutational analysis of the regulatory function of the c-Abl Src homology 3 domain.c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cellsGenetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation.Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorMurine models of acute leukemia: important tools in current pediatric leukemia research.PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in miceMechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cellsDifferential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.Signaling in leukemia: which messenger to kill?JAK-STAT signaling activated by Abl oncogenes.Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-AblFunctional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells.A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loopThe B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemiaRecent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.
P2860
Q24563301-B27245A8-0B22-41AD-86A0-465DDFE38826Q24685070-CDBDB9A9-9A38-4F2C-A2BA-656BCCD6AFA1Q24814983-A7F1CD65-C6D4-410D-A2D1-5E0B3ED71826Q24816866-B197971E-C590-41E9-9D28-465FCFDB0F82Q26745531-D1A01263-5104-4824-B29F-53A9C8560886Q26777629-B55EFC60-F417-4DB0-B782-10C9CC33D932Q27025242-49B42763-7215-4971-BD9B-32599709AA38Q27026520-981901F7-FEB5-468F-8E86-32EEAB7C4FC3Q27652166-E40F37D3-081D-441C-877C-3D4FBE4BCBF7Q27667482-E04D45BC-FE5F-4064-94B1-856F0BF10735Q28076328-80A400E3-AE9F-4360-83BD-27FDCAE69524Q28214984-A777AF3B-5D84-4C83-87A2-AC855252A4AFQ28365521-C94D5A45-F8B0-4F9D-B013-F3D5C7CA77B1Q28484079-4214B7DD-799C-477F-A7C5-2FD46C5430A3Q30167708-F724209E-EA4B-41F9-B3BD-73EBF7CD7B71Q30424785-D48F4011-8988-4C53-BB19-BB575DF8006DQ31029794-89B4F5B0-25C4-446C-8F78-EB95A78C8333Q33402499-BBC10F25-2653-4136-B73A-E1A4E7F61974Q33559005-F96F18CA-D328-47FB-9644-6C32631A36E1Q33597663-4F857D61-FAA1-43D3-B46B-305D803DA855Q33606018-EBAC3278-D0E5-48BD-95F3-DE4DFF43CD19Q33608760-A5979AC8-F5DA-4399-BBF9-ADE775031DB8Q33694514-CA13832B-6AB0-4F8F-B949-6DC7E0D3A31EQ33753325-29D67866-DB61-4230-A44B-B10160D2283BQ33806036-D618ACE0-2924-41B8-AFC3-BCA56DB1CBCEQ33899740-22DFCDAA-3C0D-438E-96EC-47BFD393E8A1Q33909737-852A951B-BE70-495B-9052-4E73CD1EE93EQ33921399-6CC9E0D0-3EBE-4C94-A80D-589E7F9B756EQ33939607-CB481D97-E19F-4E1B-A98E-7BC5160F6716Q33941370-538FF7CF-6AE0-4E5B-8063-D66FE4A8DF81Q33961815-ABFB977E-A69D-443D-B70B-11FE787906B3Q33967112-2DB278CC-37C2-4D4B-A04E-A2A9DE294A20Q34062313-4745B118-2815-4ABB-9548-79A8A1265B6AQ34064832-0D5CC09F-063A-453D-9048-72630DE7586EQ34075619-CE69A192-8F93-4AE6-9F1E-B453905809D3Q34099472-CEB281E8-D3EC-442C-8D28-FC059F56EBBDQ34117463-31E130B9-9582-456E-A257-B4C3CEC630DBQ34170309-5412DDCE-2A8E-4EEE-AF54-DBA3AA64AD13Q34193548-93080452-7196-4510-BD1E-843B39BBA37FQ34235845-57F38252-1309-4612-A78B-9DE500AFC903
P2860
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@ast
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@en
type
label
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@ast
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@en
prefLabel
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@ast
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@en
P2093
P2860
P356
P1476
The P190, P210, and P230 forms ...... ymphoid leukemogenic activity.
@en
P2093
P2860
P304
P356
10.1084/JEM.189.9.1399
P407
P577
1999-05-01T00:00:00Z